Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease
Author(s) -
Gregg W. Stone,
Joseph F. Sabik,
Patrick W. Serruys,
Charles A. Simonton,
Philippe Généreux,
John D. Puskas,
David E. Kandzari,
Marie-Claude Morice,
Nicholas Lembo,
W. Morris Brown,
David P. Taggart,
Adrian Banning,
Béla Merkely,
Ferenc Horkay,
Piet W. Boonstra,
Ad J. van Boven,
Imre Ungi,
Gábor Bogáts,
Samer Mansour,
Nicolas Noiseux,
Manel Sabaté,
José Luís Pomar,
M. Hickey,
Anthony Gershlick,
Paweł Buszman,
Andrzej Bochenek,
Erick Schampaert,
Pierre Pagé,
Ovidiu Dressler,
Ioanna Kosmidou,
Roxana Mehran,
Stuart J. Pocock,
A. Pieter Kappetein
Publication year - 2016
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1610227
Subject(s) - medicine , percutaneous coronary intervention , myocardial infarction , cardiology , conventional pci , clinical endpoint , stroke (engine) , coronary artery disease , revascularization , everolimus , bypass surgery , artery , surgery , randomized controlled trial , mechanical engineering , engineering
Patients with obstructive left main coronary artery disease are usually treated with coronary-artery bypass grafting (CABG). Randomized trials have suggested that drug-eluting stents may be an acceptable alternative to CABG in selected patients with left main coronary disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom